3-butyl-6-chloro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide | 40293-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 3-butyl-6-chloro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide
• 英文别名: 3-butyl-6-chloro-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide；3-butyl-6-chloro-4H-1λ6,2,4-benzothiadiazine 1,1-dioxide
• CAS: 40293-61-6
• 化学式: C₁₁H₁₃ClN₂O₂S
• 分子量: 272.755
• InChiKey: NIHMWAMUVJVDRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-butyl-6-chloro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 在 硫酸 、 硝酸 作用下， 生成 3-butyl-6-chloro-7-nitro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide
  参考文献：
  名称：

  Monzani; Di Bella; Fabio, Farmaco, Edizione Scientifica, 1973, vol. 28, # 2, p. 149 - 156

  摘要：

  DOI：
• 作为产物：
  描述：

  戊酸酐 、 2-氨基-4-氯苯磺胺 生成 3-butyl-6-chloro-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide
  参考文献：
  名称：

  Monzani; Di Bella; Fabio, Farmaco, Edizione Scientifica, 1973, vol. 28, # 2, p. 149 - 156

  摘要：

  DOI：

文献信息

• USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL
  申请人：De Boer Johannes Mathijs Maria

  公开号：US20100234362A1

  公开（公告）日：2010-09-16

  The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or less. The present invention also relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising orally administering to said mammal in need thereof a daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis.
• USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS
  申请人：De Boer Johannes Marthijs Maria

  公开号：US20120053172A1

  公开（公告）日：2012-03-01

  The present invention relates to a method for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug. The present invention also relates to a method for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising administering to said mammal a pharmaceutically effective amount of a combination of a potassium channel activator and an anti-diabetic drug.
• Monzani; Di Bella; Fabio, Farmaco, Edizione Scientifica, 1973, vol. 28, # 2, p. 149 - 156
  作者：Monzani、Di Bella、Fabio、Manicardi

  DOI：——

  日期：——